These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 30528042)

  • 21. Wnt/beta-catenin pathway deregulation in childhood adrenocortical tumors.
    Leal LF; Mermejo LM; Ramalho LZ; Martinelli CE; Yunes JA; Seidinger AL; Mastellaro MJ; Cardinalli IA; Brandalise SR; Moreira AC; Tone LG; Scrideli CA; Castro M; Antonini SR
    J Clin Endocrinol Metab; 2011 Oct; 96(10):3106-14. PubMed ID: 21849527
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CTNNB1 45F mutation is a molecular prognosticator of increased postoperative primary desmoid tumor recurrence: an independent, multicenter validation study.
    Colombo C; Miceli R; Lazar AJ; Perrone F; Pollock RE; Le Cesne A; Hartgrink HH; Cleton-Jansen AM; Domont J; Bovée JV; Bonvalot S; Lev D; Gronchi A
    Cancer; 2013 Oct; 119(20):3696-702. PubMed ID: 23913621
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human microRNA expression in sporadic and FAP-associated desmoid tumors and correlation with beta-catenin mutations.
    Cavallini A; Rotelli MT; Lippolis C; Piscitelli D; Digennaro R; Covelli C; Carella N; Accetturo M; Altomare DF
    Oncotarget; 2017 Jun; 8(26):41866-41875. PubMed ID: 28418912
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinicopathological features of 70 desmoid-type fibromatoses confirmed by β-catenin immunohistochemical staining and CTNNB1 mutation analysis.
    An J; Woo HY; Lee Y; Kim HS; Jeong J; Kim SK
    PLoS One; 2021; 16(4):e0250619. PubMed ID: 33914771
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of CTNNB1 mutations, CTNNB1 amplifications, and an Axin2 splice variant in juvenile angiofibromas.
    Wemmert S; Willnecker V; Kulas P; Weber S; Lerner C; Berndt S; Wendler O; Schick B
    Tumour Biol; 2016 Apr; 37(4):5539-49. PubMed ID: 26572152
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic value of CTNNB1 gene mutation in primary sporadic aggressive fibromatosis.
    van Broekhoven DL; Verhoef C; Grünhagen DJ; van Gorp JM; den Bakker MA; Hinrichs JW; de Voijs CM; van Dalen T
    Ann Surg Oncol; 2015 May; 22(5):1464-70. PubMed ID: 25341748
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Specific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors.
    Lazar AJ; Tuvin D; Hajibashi S; Habeeb S; Bolshakov S; Mayordomo-Aranda E; Warneke CL; Lopez-Terrada D; Pollock RE; Lev D
    Am J Pathol; 2008 Nov; 173(5):1518-27. PubMed ID: 18832571
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Near universal detection of alterations in CTNNB1 and Wnt pathway regulators in desmoid-type fibromatosis by whole-exome sequencing and genomic analysis.
    Crago AM; Chmielecki J; Rosenberg M; O'Connor R; Byrne C; Wilder FG; Thorn K; Agius P; Kuk D; Socci ND; Qin LX; Meyerson M; Hameed M; Singer S
    Genes Chromosomes Cancer; 2015 Oct; 54(10):606-15. PubMed ID: 26171757
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Correlation of CTNNB1 Mutation Status with Progression Arrest Rate in RECIST Progressive Desmoid-Type Fibromatosis Treated with Imatinib: Translational Research Results from a Phase 2 Study of the German Interdisciplinary Sarcoma Group (GISG-01).
    Kasper B; Gruenwald V; Reichardt P; Bauer S; Hohenberger P; Haller F
    Ann Surg Oncol; 2016 Jun; 23(6):1924-7. PubMed ID: 26861905
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Frequent CTNNB1 p.S45 Mutations and Aggressive Clinical Behavior in Neuromuscular Choristoma-Associated Fibromatosis.
    Carter JM; Maldonado AA; Howe BM; Okuno S; Spinner RJ
    Neurosurgery; 2021 Mar; 88(4):804-811. PubMed ID: 33442732
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Detection of beta-catenin mutations in paraffin-embedded sporadic desmoid-type fibromatosis by mutation-specific restriction enzyme digestion (MSRED): an ancillary diagnostic tool.
    Amary MF; Pauwels P; Meulemans E; Roemen GM; Islam L; Idowu B; Bousdras K; Diss TC; O'Donnell P; Flanagan AM
    Am J Surg Pathol; 2007 Sep; 31(9):1299-309. PubMed ID: 17721184
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic significance of
    Guo L; Wang X; Xu B; Lang R; Hu B
    Future Oncol; 2021 Feb; 17(4):435-442. PubMed ID: 33397129
    [No Abstract]   [Full Text] [Related]  

  • 33. Identification of Familial Adenomatous Polyposis carriers among children with desmoid tumours.
    Kattentidt Mouravieva AA; Geurts-Giele IR; de Krijger RR; van Noesel MM; van de Ven CP; van den Ouweland AM; Kromosoeto JN; Dinjens WN; Dubbink HJ; Smits R; Wagner A
    Eur J Cancer; 2012 Aug; 48(12):1867-74. PubMed ID: 22305464
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 'Difficult to diagnose' desmoid tumours: a potential role for CTNNB1 mutational analysis.
    Colombo C; Bolshakov S; Hajibashi S; Lopez-Terrada L; Wang WL; Rao P; Benjamin RS; Lazar AJ; Lev D
    Histopathology; 2011 Aug; 59(2):336-40. PubMed ID: 21884214
    [TBL] [Abstract][Full Text] [Related]  

  • 35. β-catenin (CTNNB1) mutations and clinicopathological features of mesenteric desmoid-type fibromatosis.
    Huss S; Nehles J; Binot E; Wardelmann E; Mittler J; Kleine MA; Künstlinger H; Hartmann W; Hohenberger P; Merkelbach-Bruse S; Buettner R; Schildhaus HU
    Histopathology; 2013 Jan; 62(2):294-304. PubMed ID: 23020601
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is immunohistochemical staining for β-catenin the definitive pathological diagnostic tool for desmoid-type fibromatosis? A multi-institutional study.
    Koike H; Nishida Y; Kohno K; Shimoyama Y; Motoi T; Hamada S; Kawai A; Ogose A; Ozaki T; Kunisada T; Matsumoto Y; Matsunobu T; Ae K; Gokita T; Sakai T; Shimizu K; Ishiguro N
    Hum Pathol; 2019 Feb; 84():155-163. PubMed ID: 30292627
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Clinicopathological and molecular genetic features of neuromuscular choristoma-associated desmoid type fibromatosis].
    Dong RF; Guo W; Li N; Wang ZY; Sun XQ; Ding Y
    Zhonghua Bing Li Xue Za Zhi; 2024 Jul; 53(7):685-690. PubMed ID: 38955699
    [No Abstract]   [Full Text] [Related]  

  • 38. Activated Signaling Pathways and Targeted Therapies in Desmoid-Type Fibromatosis: A Literature Review.
    Timbergen MJM; Smits R; Grünhagen DJ; Verhoef C; Sleijfer S; Wiemer EAC
    Front Oncol; 2019; 9():397. PubMed ID: 31165043
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of APC/beta-catenin genes mutations and Wnt signalling pathway in desmoid-type fibromatosis.
    Jilong Y; Jian W; Xiaoyan Z; Xiaoqiu L; Xiongzeng Z
    Pathology; 2007 Jun; 39(3):319-25. PubMed ID: 17558858
    [TBL] [Abstract][Full Text] [Related]  

  • 40. AXIN deficiency in human and mouse hepatocytes induces hepatocellular carcinoma in the absence of β-catenin activation.
    Abitbol S; Dahmani R; Coulouarn C; Ragazzon B; Mlecnik B; Senni N; Savall M; Bossard P; Sohier P; Drouet V; Tournier E; Dumont F; Sanson R; Calderaro J; Zucman-Rossi J; Vasseur-Cognet M; Just PA; Terris B; Perret C; Gilgenkrantz H
    J Hepatol; 2018 Jun; 68(6):1203-1213. PubMed ID: 29525529
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.